Esther Gerteis Appointed VP Medical Affairs of CorFlow

Baar, Switzerland, February 1st 2018

CorFlow Therapeutics AG today announced that Mrs. Esther Gerteis has been appointed CorFlow’s VP Medical Affairs and will be a member of the CorFlow Management team.

Esther has enjoyed an impressive career in cardiovascular clinical trial strategy and execution. She joins CorFlow from Edwards Lifesciences where she served as their Senior Director Clinical Affairs in Edwards’ Transcatheter Mitral and Tricuspid Therapy Business Unit. She has more than 13 years’ experience with Edwards implementing clinical trials and also established the Clinical Affairs department as Director Clinical Affairs Vascular Interventions in Biotronik within 7 years. Esther has a wide network in the interventional cardiology community and will be responsible for the worldwide clinical strategy, educational and publication activities in CorFlow.

Jon H. Hoem, CorFlow’s CEO and Co-Founder, said: “I’m delighted to finally be able to work with Esther. As I have followed her career over many years, I’m impressed by her hard work, dedication and knowledge in cardiovascular clinical trial design and execution. Her integrity is an essential part of her work ethic which will serve CorFlow well in a time where clinical data is the key to any emerging medical device company’s success.”

Esther joins CorFlow at an important time point while the company is finalising the Clinical Investigation Plan for it’s First-in-Man MOCA I – “MVO with CoFI™ System Assessment I” clinical trial. This trial will investigate the ability of the CorFlow Controlled Flow Infusion (CoFI™) system to diagnose and treat microvascular obstruction (MVO) in severe heart attack patients.

Esther commented regarding her new appointment: “The CorFlow CoFI™ technology constitutes a potential breakthrough in how heart attack patients are managed immediately following revascularization. This technology could reduce complications and costs for thousands of heart attack patients every year and may avoid functional structural heart damage. I’m excited to join the CorFlow team now and to build on the momentum that has been created in the early phase of the company.”

The CorFlow team during a recent meeting in the CorFlow headquarters in Baar, Switzerland. The team is co-located to facilitate and shorten the communication paths and improve quality in the dynamic early phases of the company. From left to right: Blathnaid Feldman (VP Quality & Regulatory Affairs), Caroline G. Hoem (Finance & Office Manager), Jon H. Hoem (CEO & Co-Founder), Esther Gerteis (VP Medical Affairs) and Oliver Bludau (R&D Manager). For a complete overview of the CorFlow Founding Team, Board of Directors and management team, please visit the CorFlow team pages.

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *

five − 1 =